Cargando…

Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis

BACKGROUND: The monoclonal antibody (mAb) trastuzumab is part of the standard of care for patients with human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer. Antibody-dependent cell-mediated phagocytosis (ADCP) and cytotoxicity (ADCC) are major mechanisms of action of the mAb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laengle, Johannes, Kabiljo, Julijan, Hunter, Leah, Homola, Jakob, Prodinger, Sophie, Egger, Gerda, Bergmann, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057438/ https://www.ncbi.nlm.nih.gov/pubmed/31940587 http://dx.doi.org/10.1136/jitc-2019-000195

Ejemplares similares

From threat to cure: understanding of virus-induced cell death leads to highly immunogenic oncolytic influenza viruses
por: Kabiljo, Julijan, et al.
Publicado: (2020)

Effects of valproic acid on histone deacetylase inhibition in vitro and in glioblastoma patient samples
por: Berendsen, Sharon, et al.
Publicado: (2019)

Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients
por: Petricevic, Branka, et al.
Publicado: (2013)

TIGIT blockade repolarizes AML-associated TIGIT(+) M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis
por: Brauneck, Franziska, et al.
Publicado: (2022)

Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase
por: Di Gennaro, E, et al.
Publicado: (2010)

Radiotherapy as a Backbone for Novel Concepts in Cancer Immunotherapy
por: Kabiljo, Julijan, et al.
Publicado: (2019)

Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01
por: Yeow, W-S, et al.
Publicado: (2006)

Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo
por: Hrzenjak, Andelko, et al.
Publicado: (2010)

Effect of histone deacetylase inhibitor (vorinostat) on new-onset diabetes induced by tacrolimus
por: Bakhdar, Fatmah A., et al.
Publicado: (2022)

Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer—Immun-HER trial (GOIRC-01-2016)
por: Pellegrino, Benedetta, et al.
Publicado: (2023)

Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer
por: Waks, Adrienne G, et al.
Publicado: (2022)

Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma
por: Saelen, Marie Grøn, et al.
Publicado: (2012)

Anti-tumor effects of the histone deacetylase inhibitor vorinostat on canine urothelial carcinoma cells
por: Eto, Shotaro, et al.
Publicado: (2019)

Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma
por: Cheriyath, V, et al.
Publicado: (2011)

Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression
por: Bruni, Sofia, et al.
Publicado: (2023)

Histone deacetylases inhibition by SAHA/Vorinostat normalizes the glioma microenvironment via xCT equilibration
por: Wolf, Ines M. L., et al.
Publicado: (2014)

Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells
por: Phillip, Cornel J, et al.
Publicado: (2012)

Improved Anticancer Activities of a New Pentafluorothio-Substituted Vorinostat-Type Histone Deacetylase Inhibitor
por: Goehringer, Nils, et al.
Publicado: (2021)

Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma
por: Kawaguchi, Y, et al.
Publicado: (2007)

Histone deacetylase inhibitors enhance estrogen receptor beta expression and augment agonist-mediated tumor suppression in glioblastoma
por: Pratap, Uday P, et al.
Publicado: (2021)

Vorinostat in the acute neuroinflammatory form of X‐linked adrenoleukodystrophy
por: Zierfuss, Bettina, et al.
Publicado: (2020)

Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma
por: O'Connor, O A
Publicado: (2006)

Effects of the Histone Deacetylase Inhibitor Valproic Acid on Human Pericytes In Vitro
por: Karén, Jakob, et al.
Publicado: (2011)

Effects of histone deacetylase inhibitor valproic acid on skeletal myocyte development
por: Li, Qiao, et al.
Publicado: (2014)

(89)Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs
por: van der Veen, Elly L, et al.
Publicado: (2020)

Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysis
por: Dahut, Madeline, et al.
Publicado: (2023)

Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis
por: Vogiatzi, Fotini, et al.
Publicado: (2022)

Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor
por: Richon, V M
Publicado: (2006)

The Mechanism of Action of the Histone Deacetylase Inhibitor Vorinostat Involves Interaction with the Insulin-Like Growth Factor Signaling Pathway
por: Sarfstein, Rive, et al.
Publicado: (2011)

Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker
por: Munster, P N, et al.
Publicado: (2009)

The Histone Deacetylase Inhibitor, Vorinostat, Represses Hypoxia Inducible Factor 1 Alpha Expression through Translational Inhibition
por: Hutt, Darren M., et al.
Publicado: (2014)

Histone Deacetylase Inhibitors Romidepsin and Vorinostat Promote Hepatitis B Virus Replication by Inducing Cell Cycle Arrest
por: Yang, Yang, et al.
Publicado: (2021)

Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis
por: Zou, Fangwen, et al.
Publicado: (2021)

Activin-A impairs CD8 T cell-mediated immunity and immune checkpoint therapy response in melanoma
por: Pinjusic, Katarina, et al.
Publicado: (2022)

STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer
por: Ding, Liya, et al.
Publicado: (2023)

Inhibition of histone deacetylation with vorinostat does not prevent tunicamycin-mediated acute kidney injury
por: Carlisle, Rachel E., et al.
Publicado: (2021)

Homocitrullination of lysine residues mediated by myeloid-derived suppressor cells in the tumor environment is a target for cancer immunotherapy
por: Cook, Katherine W, et al.
Publicado: (2021)

Migration, Proliferation, and Differentiation of Cord Blood Mesenchymal Stromal Cells Treated with Histone Deacetylase Inhibitor Valproic Acid
por: Marquez-Curtis, Leah A., et al.
Publicado: (2014)

Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors
por: Moreaux, J, et al.
Publicado: (2013)

Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses
por: Brentville, Victoria A, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bb2gnca8u3f8ra15guef6b8l47